Condition or disease | Intervention/treatment |
---|---|
Intracranial Aneurysm | Device: FRED and FRED Jr |
This is a multi-center observational study. Treatment and follow-up visits will be performed as per standard of care. The purpose of this study is to demonstrate that use of the FREDTM/FREDTM Jr Embolic device in intracranial aneurysm treatment is safe and effective when assessed at 6, 12 months and yearly up to 5 years post procedure.
150 patients will be enrolled over an 15-month recruitment period. All patients will be followed for 5 years.
Study Type : | Observational |
Estimated Enrollment : | 150 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | FRED/FRED Jr Intracranial Aneurysm Treatment Study |
Actual Study Start Date : | April 10, 2019 |
Estimated Primary Completion Date : | April 30, 2021 |
Estimated Study Completion Date : | September 30, 2024 |
Complete occlusion (Raymond Scale grade I) without stenosis of the parent artery.
Raymond scale definition: Grade I= complete occlusion of aneurysm, Grade II= Residual neck, Grade III= Residual aneurysm
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date | April 15, 2019 | ||||||||
First Posted Date | April 18, 2019 | ||||||||
Last Update Posted Date | April 18, 2019 | ||||||||
Actual Study Start Date | April 10, 2019 | ||||||||
Estimated Primary Completion Date | April 30, 2021 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures |
|
||||||||
Original Primary Outcome Measures | Same as current | ||||||||
Change History | No Changes Posted | ||||||||
Current Secondary Outcome Measures | Not Provided | ||||||||
Original Secondary Outcome Measures | Not Provided | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title | FRED/FRED Jr Intracranial Aneurysm Treatment Study | ||||||||
Official Title | FRED/FRED Jr Intracranial Aneurysm Treatment Study | ||||||||
Brief Summary | A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED® device in the treatment of intracranial aneurysms | ||||||||
Detailed Description |
This is a multi-center observational study. Treatment and follow-up visits will be performed as per standard of care. The purpose of this study is to demonstrate that use of the FREDTM/FREDTM Jr Embolic device in intracranial aneurysm treatment is safe and effective when assessed at 6, 12 months and yearly up to 5 years post procedure. 150 patients will be enrolled over an 15-month recruitment period. All patients will be followed for 5 years. |
||||||||
Study Type | Observational | ||||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||||||
Target Follow-Up Duration | Not Provided | ||||||||
Biospecimen | Not Provided | ||||||||
Sampling Method | Non-Probability Sample | ||||||||
Study Population | Patients who are at least 18 years of age presenting with an unruptured or recanalized intracranial aneurysm requiring endovascular treatment. Those eligible to be treated with FRED/FRED Jr will be enrolled after having signed an informed consent form. | ||||||||
Condition | Intracranial Aneurysm | ||||||||
Intervention | Device: FRED and FRED Jr
Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
Other Name: Flow Re-Direction Endoluminal Device
|
||||||||
Study Groups/Cohorts | Not Provided | ||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status | Recruiting | ||||||||
Estimated Enrollment |
150 | ||||||||
Original Estimated Enrollment | Same as current | ||||||||
Estimated Study Completion Date | September 30, 2024 | ||||||||
Estimated Primary Completion Date | April 30, 2021 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender |
|
||||||||
Ages | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts |
|
||||||||
Listed Location Countries | Germany | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number | NCT03920358 | ||||||||
Other Study ID Numbers | CIP EMEA 18-01 | ||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement |
|
||||||||
Responsible Party | Microvention-Terumo, Inc. | ||||||||
Study Sponsor | Microvention-Terumo, Inc. | ||||||||
Collaborators | Not Provided | ||||||||
Investigators |
|
||||||||
PRS Account | Microvention-Terumo, Inc. | ||||||||
Verification Date | April 2019 |